{"id":955300,"date":"2026-04-28T08:04:48","date_gmt":"2026-04-28T12:04:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\/"},"modified":"2026-04-28T08:04:48","modified_gmt":"2026-04-28T12:04:48","slug":"annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\/","title":{"rendered":"Annovis Publishes Phase 2\/3 Alzheimer&#8217;s Trial Results in Nature Portfolio"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>Buntanetap improved cognition in pTau217-positive early AD patients<\/li>\n<li>The drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegeneration<\/li>\n<li>Buntanetap was safe and well-tolerated, including in ApoE4 carriers<\/li>\n<li>Phase 2\/3 findings support ongoing pivotal Phase 3 study in early AD, with 80% patients enrolled to date\n<\/li>\n<\/ul>\n<p>MALVERN, Pa., April  28, 2026  (GLOBE NEWSWIRE) &#8212; Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer&#8217;s disease (AD) and Parkinson&#8217;s disease (PD), today announced a new publication titled \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3fZl2Pexo1nXhgjqTYzu9FTiw5lKS58as5gSh0fXKeYh0d-vGKwjbAemG5ZhLcU2hzzIFvJAbekPyaINr4gFplJUouzZRN5XbT4uFnkIpwctX6C_-wjayzaXLZiqfpWBJ5g8K04_0yGzybjYKifiGjFLvaxLqOcUS5TPigsFtcyjiPxsjHZz4GMM5z3iNgqAh6SrlVCkxIsZNoNb3_16RA==\" rel=\"nofollow\" target=\"_blank\">Buntanetap treatment in mild to moderate Alzheimer\u2019s disease: phase 2\/3 study<\/a>\u201d in a peer-reviewed journal <em>Nature NPJ Dementia<\/em>.<\/p>\n<p>The Phase 2\/3 study (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=n9DK9dcrai4C59x2ldyXeID6Drz0uiNIXMQp9XP98BlhOMgvwk_Dis2UKIB8qDR6OgR7aMAyocIHOjX7QPaXVQ5XwsPq0J1DcUztjD09ip0OnPjnVadhm4pirTzOrNmRSmcIplkE7ZhJx7U2ffLVxw==\" rel=\"nofollow\" target=\"_blank\">NCT05686044<\/a>) was a randomized, double-blinded, placebo-controlled trial evaluating three doses of buntanetap (7.5 mg, 15 mg, and 30 mg) over 12 weeks in 351 patients with mild to moderate AD. The study demonstrated that buntanetap was safe and well-tolerated across all disease stages and dose levels. Notably, safety was also assessed in ApoE4 carriers, the most genetically at-risk population for AD, with no increase in adverse events compared to non-carriers and to placebo. Given buntanetap&#8217;s distinct mechanism of action, the drug was also well-tolerated when taken alongside approved symptomatic therapies, allowing patients to maintain their existing medication regimens without the need for discontinuation.<\/p>\n<p>Study analyses revealed statistically significant, dose-dependent improvements in cognition, as measured by ADAS-Cog11, in pTau217 biomarker-positive patients with mild AD (MMSE 21\u201324). Moreover, at the 30 mg dose, buntanetap demonstrated a consistent treatment effect across all analyzed patient groups when stratified by age, body mass index, sex, ethnicity, ApoE4 carrier status, and concomitant medication use, with favorable effects versus placebo observed across each of these groups.<\/p>\n<p>Biomarker analyses further revealed reductions in neurotoxic proteins TDP-43 and tau, in the markers of neuroinflammation, including IL-5, IL-6, S100A12, IFN-\u03b3, and IGF1R, as well as in the marker of neurodegeneration, neurofilament light chain (NfL), pointing to potential disease-modifying activity. Importantly, the same trends were observed in plasma samples from patients with moderate AD, further supporting buntanetap&#8217;s mechanism of action.<\/p>\n<p>&#8220;The publication of these results in a peer-reviewed journal marks an important step in the scientific validation of buntanetap,&#8221; said Cheng Fang, Ph.D., Senior Vice President, Research &amp; Development. &#8220;The data reinforce what we have seen across multiple studies: buntanetap addresses the underlying pathology of AD with a safety profile that supports its use in a broad, genetically diverse patient population. The treatment effect we observed in biomarker-confirmed early AD patients provides strong scientific rationale as we advance our drug candidate through a pivotal Phase 3 study.&#8221;<\/p>\n<p>Buntanetap is currently being investigated in a pivotal Phase 3 clinical trial enrolling pTau217 biomarker-positive patients with early AD (MMSE 20\u201328) (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7YhIqeKKGVCnWQPhjyZVsXIRVGC2S5DpliLFvEGwlx7qZDqNKO_Rh89l7_lAd9fEIDmEI0FDtqj6-L4DjXdlhILKCvSsg-wAaFOS5DuiMPF7d2nDViyUZSX23pFwaO2PmQkjk5HaWH8ihFN4otATGg==\" rel=\"nofollow\" target=\"_blank\">NCT06709014<\/a>). The trial is designed to replicate and extend the findings of the Phase 2\/3 study, evaluating the efficacy of buntanetap at 6 and 18 months, measuring symptomatic and potential disease-modifying benefits, respectively. The study is nearing full enrollment, with 80% of patients already enrolled.<\/p>\n<p>\n        <strong>About Annovis<\/strong><br \/>\n        <br \/>Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer&#8217;s disease (AD) and Parkinson&#8217;s disease (PD). The Company&#8217;s lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ou6uJ8ZZB2qDw8chzezUFdR9Qc52p7PYwuPHESG65f2XiNp-Q7K_miQR_kl1GfDXlVQPBHadESKjS1AU3BGncvASobFeBIBzkvVIi7s-cASB2fKzcUcuisWRQXk2c2NVsd0oAulVArJ95eT2lJcTZxOogfb5Ih3necaRTPXYwB4iZWNf0ZoYDRl05iQsad-XCvIXRc-SSpy9T1Hhpo2-ci4Vmk9lYvesZ9-iGALDd7QY2dPW8izABIJ-_1zGIHFoX1C36PS-K25Tv6vYj1mXfg==\" rel=\"nofollow\" target=\"_blank\">www.annovisbio.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=__SIbW8H5vhPy4L8dXI8XFj962tD3gtvOU5JY2iGLKBiiQnaYu09M92fp8WxLex11749vLocqvoQckOzKOgSMir5GSrLXJLel4dZzKn-_EQLKYGUb49IG10DHF17XwIYI8TgcJdqMGI1ipIo8pWbb9Ut3F8E262qzzzH0jkk02bnuATyLcphTG8FxGjBb0owy2NTuJ0td8TTRf11mv4pRVfbNGjiDiUyqY2E_Fo2BZql4qKtktgDsHR6zAQvCZI1HuOTfW94beLkhlb-R5j3I78isRfHJd-m5vVVf8rCve5cDYSkYILdLqw6AQYnuiKs\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vELg_9LdU67BjTUO2TLIRIZA4CIhkZhx4tpW-4CeK-sYwfKYkx9Cm2RSMJiPnKOhnbmMFZBgDiCnVeohj6lz6z_Yz7i-QsABsr7Jk1tCzBD1xxoNCyts3Cp5yhHn1l22jXY_RZXcrzdBqD2a_KGweB5Y52XA5cpnnM0OpVYr7B0NXgDBtKseHA85szUhOWMPAFoTbNa_Zu5kNIhF_mbT2S1M-eo-_Rv-8vkCJX8L7udl5m7dhej2k8VH9QjGUkzZ\" rel=\"nofollow\" target=\"_blank\">YouTube<\/a>, and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5I344r0Y-xZ2HjWCl4L2-W8dU72I9Aq-uMwHBmee8yFN9QO4yF3uGRDyF3vjlcqjE2c5DcLt6I6qQ74A-iiLX-IB6UdoYUjfFAjv-tKBjbmD9vvDZfN-qHVt0PTjxj6ImVczNxz0QgRGFbGiaAAeqyCeSbXHGmrtKUESlx4SGMWQd3jORIAuQhyrS6qNZqPMuznbAuUTmOE2yKzm8EsQmg==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>\n        <strong>Investor Alerts<\/strong><br \/>\n        <br \/>Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8FEIpFdxmyEsAvKP7Qn46ndeim3G9s3cS7NehqANYxBDTKYUsCzmsRW1DayEt_ua9dgvGo39hdjGOEzWtDbFdu8KLICA9eN9dCW9QZFOkfx6G9Q38AH6UMHXKP9_F2E2QXuCDT6HnWcKDYXBhd6XITSlR_07L7X5TVWmixSWRfRr7AVSpdEFqY4E2qd05YKjq5HhAeRGqzOeRkIe19NreWZfuyZW39J1lao3guUKpZktfKCpG4l6dBiRiTaE9LAVMXjH4McOvRTsotXLQ5xAliXrDPHjHE8WE6TCKOkr3Ln8lk14bPekaG1ncF9V88gN_h7AfDaaay_JaLFLn3FNxBSUqZwA-XJf3o6SmG6aGQ0=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.annovisbio.com\/email-alerts<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company\u2019s SEC filings under \u201cRisk Factors\u201d in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.<\/p>\n<p>\n        <strong>Contact Information:<\/strong><br \/>\n        <br \/>Annovis Bio Inc.<br \/>101 Lindenwood Drive<br \/>Suite 225<br \/>Malvern, PA 19355<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ou6uJ8ZZB2qDw8chzezUFb1Vf9Fh-kxf-n_LfjJ6uvLbeatoaolT11YUADwyYN7xMlOiT7WyBKRlaVoSAbo_Omy2SmjTphRioHMuvFrHsHXwv1JEmlrgIY9aIws-stR6mdXii9_yAYre8l7ceUzDJUVB95PPGEYrLttN4NIWE_2z_xcijLGrL4VKTxqzCiGnDW8BYIion0CrYCZqYSbx67tGswf6STkncyQWf02PpLCe9AfliSunTvRfQ_hLX7Fym0gJ6b_5yD_oauOf65WWrw==\" rel=\"nofollow\" target=\"_blank\">www.annovisbio.com<\/a><\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Alexander Morin, Ph.D.<br \/>Director, Strategic Communications<br \/>Annovis Bio<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=e8-mz1cMIoQkjuq0qv74IXkTQYqXyQMOkFwsj9LZ-IFt9PBZnKHMOFqY09SUBEPN9bScqAAhW78RWvoWIHR2_oU1A25xi2GOD5wN9ls0V3s=\" rel=\"nofollow\" target=\"_blank\">ir@annovisbio.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwODQyNSM3NTY5NTA3IzIxOTQ4NTA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjcwYjA1ODktNDgzOC00YTEzLWI1NTAtOWU5MmI0MjlmMWJkLTEyMDY0MDMtMjAyNi0wNC0yOC1lbg==\/tiny\/Annovis-Bio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Buntanetap improved cognition in pTau217-positive early AD patients The drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegeneration Buntanetap was safe and well-tolerated, including in ApoE4 carriers Phase 2\/3 findings support ongoing pivotal Phase 3 study in early AD, with 80% patients enrolled to date MALVERN, Pa., April 28, 2026 (GLOBE NEWSWIRE) &#8212; Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer&#8217;s disease (AD) and Parkinson&#8217;s disease (PD), today announced a new publication titled \u201cBuntanetap treatment in mild to moderate Alzheimer\u2019s disease: phase 2\/3 study\u201d in a peer-reviewed journal Nature NPJ Dementia. The Phase 2\/3 study (NCT05686044) was a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Annovis Publishes Phase 2\/3 Alzheimer&#8217;s Trial Results in Nature Portfolio&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-955300","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Annovis Publishes Phase 2\/3 Alzheimer&#039;s Trial Results in Nature Portfolio - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Annovis Publishes Phase 2\/3 Alzheimer&#039;s Trial Results in Nature Portfolio - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Buntanetap improved cognition in pTau217-positive early AD patients The drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegeneration Buntanetap was safe and well-tolerated, including in ApoE4 carriers Phase 2\/3 findings support ongoing pivotal Phase 3 study in early AD, with 80% patients enrolled to date MALVERN, Pa., April 28, 2026 (GLOBE NEWSWIRE) &#8212; Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer&#8217;s disease (AD) and Parkinson&#8217;s disease (PD), today announced a new publication titled \u201cBuntanetap treatment in mild to moderate Alzheimer\u2019s disease: phase 2\/3 study\u201d in a peer-reviewed journal Nature NPJ Dementia. The Phase 2\/3 study (NCT05686044) was a &hellip; Continue reading &quot;Annovis Publishes Phase 2\/3 Alzheimer&#8217;s Trial Results in Nature Portfolio&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-28T12:04:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwODQyNSM3NTY5NTA3IzIxOTQ4NTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Annovis Publishes Phase 2\\\/3 Alzheimer&#8217;s Trial Results in Nature Portfolio\",\"datePublished\":\"2026-04-28T12:04:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\\\/\"},\"wordCount\":719,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwODQyNSM3NTY5NTA3IzIxOTQ4NTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\\\/\",\"name\":\"Annovis Publishes Phase 2\\\/3 Alzheimer's Trial Results in Nature Portfolio - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwODQyNSM3NTY5NTA3IzIxOTQ4NTA=\",\"datePublished\":\"2026-04-28T12:04:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwODQyNSM3NTY5NTA3IzIxOTQ4NTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwODQyNSM3NTY5NTA3IzIxOTQ4NTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Annovis Publishes Phase 2\\\/3 Alzheimer&#8217;s Trial Results in Nature Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Annovis Publishes Phase 2\/3 Alzheimer's Trial Results in Nature Portfolio - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\/","og_locale":"en_US","og_type":"article","og_title":"Annovis Publishes Phase 2\/3 Alzheimer's Trial Results in Nature Portfolio - Market Newsdesk","og_description":"Buntanetap improved cognition in pTau217-positive early AD patients The drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegeneration Buntanetap was safe and well-tolerated, including in ApoE4 carriers Phase 2\/3 findings support ongoing pivotal Phase 3 study in early AD, with 80% patients enrolled to date MALVERN, Pa., April 28, 2026 (GLOBE NEWSWIRE) &#8212; Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer&#8217;s disease (AD) and Parkinson&#8217;s disease (PD), today announced a new publication titled \u201cBuntanetap treatment in mild to moderate Alzheimer\u2019s disease: phase 2\/3 study\u201d in a peer-reviewed journal Nature NPJ Dementia. The Phase 2\/3 study (NCT05686044) was a &hellip; Continue reading \"Annovis Publishes Phase 2\/3 Alzheimer&#8217;s Trial Results in Nature Portfolio\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-28T12:04:48+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwODQyNSM3NTY5NTA3IzIxOTQ4NTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Annovis Publishes Phase 2\/3 Alzheimer&#8217;s Trial Results in Nature Portfolio","datePublished":"2026-04-28T12:04:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\/"},"wordCount":719,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwODQyNSM3NTY5NTA3IzIxOTQ4NTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\/","name":"Annovis Publishes Phase 2\/3 Alzheimer's Trial Results in Nature Portfolio - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwODQyNSM3NTY5NTA3IzIxOTQ4NTA=","datePublished":"2026-04-28T12:04:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwODQyNSM3NTY5NTA3IzIxOTQ4NTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwODQyNSM3NTY5NTA3IzIxOTQ4NTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-publishes-phase-2-3-alzheimers-trial-results-in-nature-portfolio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Annovis Publishes Phase 2\/3 Alzheimer&#8217;s Trial Results in Nature Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/955300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=955300"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/955300\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=955300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=955300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=955300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}